Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase

Leukemia and Lymphoma

Volumn 31, Issue 1-2, 1998, Pages 143-149

  Ek, Onur ^a   Gaynon, Paul ^c   Zeren, Tamer ^a   Chelstrom, Lisa M ^b   Myers, Dorothea E ^b   Uckun, Fatih M ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Department of Genetics   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Anti CD19 immunotoxin B43 PAP; Human B cell precursor leukemia; L asparaginase; Methyl prednisolone; NALM 6 cells; SCID mice; Standard chemotherapy; Vincristine

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; B43 PAP; CD19 ANTIGEN; DAUNORUBICIN; IMMUNOTOXIN; METHYLPREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CANCER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SCID MOUSE;

EID: 0031685787     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057594     Document Type: Article

References (18)

1. Trigg, M. E., Gaynon, P. and Uckun, F. M. (1996). Acute lymphoblastic leukemia in children. In: J. F. Holland, E. I. Fry, R. C. J. Bast, D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, 4th edition, pp. 1-15. (Williams & Wilkins, Philadelphia, PA).
2. Pui, C. H. (1995). Childhood leukemias. New Engl J Med, 332, 1618-1630.
3. Rivera, G. K., Pinkel, D., Simone, J. V., Hancock, M. L. and Crist, W. M. (1993). Treatment of acute lymphoblastic leukemia. N Engl J Med, 1289-1295.
4. Poplack, D. J. (1989). Acute lymphoblastic leukemia. In: P. A. Pizzo, and D. G. Poplack (eds.), Principles and Practice of Pediatric Oncology, pp. 323-366 (J. B. Lippincott, Philadelphia: PA).
5. Sallan, S. E. and Weinstein, H. J. (1987). Childhood acute leukemia. In: D. G. Nathan, and F. Oski, A. (eds.), Hematology of Infancy and Childhood, 3rd edition, pp. 1028-1063 (W. B. Saunders Co., Philadelphia, PA).
6. Ortega, J. A., Nesbit, M. E., Jr., Donaldson, M. H., Hittle, R. E., Weiner, J., Karon, M. and Hammond, D. (1977). L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res, 37, 535-540.
7. Feig, S. A., Ames, M. M., Sather, H. N., Steinherz, L., Reid, J. M., Trigg, M., Pendergrass, T. W., Warkentin, P., Gerver, M., Leonard, M., Bleyer, W. R. and Harris, R. E. (1996). Comparison of idarubicin to daunorubicin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from The Children's Cancer Group. Med Pediatr Oncol, 27, 505-514.
8. Simone, J. V. (1981). Optimal current treatment of childhood acute lymphoblastic leukemia. Cancer Treat Rep, 65 (Suppl. 4), 97-100.
9. Uckun, F. M. (1993). Immunotoxin therapy of human lymphoid malignancies. Br J Haematol, 85, 435-438.
10. Uckun, F. M. and Reaman, G. H. (1995). Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma, 18, 195-201.
11. Irvin, J. D. and Uckun, F. M. (1992). Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. Pharmacol Ther, 55, 279-302.
12. + human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood, 79, 3116-3129.
13. Uckun, F. M., Manivel, C., Arthur, D., Chelstrom, L. M., Finnegan, D., Tuel-Ahlgren, L., Irvin, J. D., Myers, D. E. and Gunther, R. (1992). In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood, 79, 2201-2214.
14. Uckun, F. M., Gajl-Peczalska, K. J., Kersey, J. H., Houston, L. L. and Vallera, D. A. (1986). Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J Exp Med, 163, 347-368.
15. Waddick, K. G., Myers, D. E., Gunther, R., Chelstrom, L. M., Chandan-Langlie, M., Irvin, J. D., Turner, N. and Uckun, F. M. (1995). In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. Blood, 86, 4228-4233.
16. Myers, D.E., Irvin, J.D., Smith, R. S., Kuebelbeck, V. M. and Uckun, F. M. (1991). Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J Immunol Methods, 136, 221-37.
17. Uckun, F. M. (1996). Severe combined immunodeficient mouse models of human leukemia. Review article, Blood, 88, 1135-1146.
18. Messinger, Y., Yanishevski, Y., Avramis, V., Ek, O., Chelstrom, L., Gunther, R., Myers, D., Irvin, J., Evans, W. and Uckun, F. M. (1996). Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside. Clinical Cancer Research, 2, 1533-1542.